Dr. Marc Siegel says a brand new experimental tablet developed to deal with COVID-19 may very well be the “holy grail of therapeutics” used towards the virus. First-stage testing of Molnupiravir, developed by Merck and Ridgeback Biotherapeutics, confirmed promising indicators of effectiveness in lowering the virus in sufferers.
“It’s really one thing you could tackle the primary day,” Siegel mentioned on “America’s Newsroom” on Monday.
“In trials, section two trials, it’s displaying that it removes the virus utterly, to the place you possibly can’t see any proof of the virus,” he added. “So it cuts down dramatically on the severity of circumstances.”
The Fox News medical contributor instructed Dana Perino the drug nonetheless must be examined on bigger teams of individuals.
“What’s left is to strive it in 1000’s and 1000’s of individuals,” Siegel mentioned. “And if that goes via and that works, then we’re going to have one thing we actually, really want.”
“What’s actually necessary is that it’s secure thus far … Of all the medication we’ve been testing, it’s the primary one we’re seeing that will actually work very, very early,” he mentioned. Siegel added that the drug may very well be useful “for those who get [coronavirus] even regardless of being vaccinated, or individuals who haven’t but been vaccinated, or individuals who can’t be vaccinated.”
The remedy would operate as an at-home, five-day therapy, much like Tamiflu, to cease the virus from reproducing earlier than inflicting main harm. It would require a prescription from a health care provider, Siegel mentioned.
“A variety of sufferers that I feel have flu, I give them Tamiflu,” he mentioned. “If I had sufferers that I assumed had COVID, I’d give them this.”
Fox News’ Angelica Stabile contributed to this report.